F B, J F, I S, RL S, LA T, A J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
 Berardi R, Maccaroni E, Mantello G, Onofri A, Mandolesi A, Bearzi I, et al. Locally advanced rectal cancer: new findings in anticancer therapy. Colorectal Cancer. 2013;2(6):585-601.
 NJ B, M D, S R, D C, D T, R A, et al. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials. 2017;18(1):394.
 J B, F S, MR S, S B, RI S, R P, et al. Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy. Dis Colon Rectum. 2016;59(10):925-33.
 M M, RG B-T, DM L, G L, PJ N, SM E, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(35):4633-40.
 Smith JJ, Garcia-Aguilar J. Advances and Challenges in Treatment of Locally Advanced Rectal Cancer. J Clin Oncol. 2015;33(16):1797-808.
 R S, C D, A J. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104-17.
 GJ G, KA C, CS R, PG H, DC M, SJ C. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-30.
 Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
 CS R, JM S, PG H, KA O, DC M. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2009;13(11):2011-8; discussion 8-9.
 DC M. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-40.
 D I, M N, C T, H K, T T, J H, et al. The Role of Neutrophil-to-lymphocyte Ratio on the Effect of CRT for Patients With Rectal Cancer. In vivo (Athens, Greece). 2020;34(2):863-8.
 TG K, W P, DH C, HC P, SH K, YB C, et al. Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. Radiation oncology journal. 2017;35(3):217-26.
 IH L, S H, SJ L, BW K, D B, HJ K, et al. Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. Anticancer Res. 2017;37(3):1459-65.
 C K, S S, RM M, K L, S S, S B, et al. Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. Medicine. 2019;98(24):e14834.
 WH W, N G, KJ R, AC E, F L, ER S, et al. Predictive Value of Leukocyte- and Platelet-Derived Ratios in Rectal Adenocarcinoma. The Journal of surgical research. 2018;232:275-82.
 IY K, SH Y, YW K. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 2014;14:94.
 M K, K R, S A, S M, S W, I P, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology. 2013;85(1):27-32.
 L S, H Z, L L, G L, M F, Y W, et al. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol. 2014;9:295.
 MR W. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018;25(6):1454-5.
 AM M, F D, JC M, J M, M H-A, JF P, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680-6.
 D H, RA W. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
 J Z, HY Z, J L, XY S, CX Z. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(40):68837-46.
 KL M, AGMT P, WG L. Systematic Review and Meta-Analysis of the Prognostic Significance of Neutrophil-Lymphocyte Ratio (NLR) After R0 Gastrectomy for Cancer. J Gastrointest Cancer. 2018;49(3):237-44.
 Y Z, S Z, Y L, L Z, X S. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer. 2018;18(1):443.
 TG K, W P, H K, DH C, HC P, SH K, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori. 2019;105(5):434-40.
 BA W. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6-23.
 D C, M C, A C, V LV, M F, R C. Neutrophil to Lymphocyte Ratio (NLR) and Derived Neutrophil to Lymphocyte Ratio (d-NLR) Predict Non-Responders and Postoperative Complications in Patients Undergoing Radical Surgery After Neo-Adjuvant Radio-Chemotherapy for Rectal Adenocarcinoma. Cancer Invest. 2016;34(9):440-51.
 Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH, et al. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019;105(5):1065-73.
 Byun HK, Kim N, Yoon HI, Kang SG, Kim SH, Cho J, et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiat Oncol. 2019;14(1):51.
 Liu H, Wang H, Wu J, Wang Y, Zhao L, Li G, et al. Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance. Radiother Oncol. 2019;131:52-9.